[Correlation analysis between LINC00324 and immunophenotype in peripheral blood leukocytes in patients with acute
Yi Liu1, Yangyang Zhang1, Jiaying Xie1
1Department of Biochemistry and Molecular Biochemistry, Guangxi Medical University, Nanning 530021, China.
Insights
Long-chain intergenic non-coding RNA324 (LINC00324) is down-regulated in acute myeloid leukemia (AML) and correlates with specific immunophenotypes. This finding suggests LINC00324 as a potential target for novel AML therapies.
Area of Science:
- Hematology
- Molecular Biology
- Immunology
Background:
- Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
- Understanding the molecular mechanisms underlying AML pathogenesis is crucial for developing targeted therapies.
- Long-chain intergenic non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer, but their specific involvement in AML requires further elucidation.
Purpose of the Study:
- To investigate the relationship between long-chain intergenic non-coding RNA324 (LINC00324) expression and immunophenotypes in acute myeloid leukemia (AML) patients.
- To explore the potential of LINC00324 as a biomarker or therapeutic target in AML.
Main Methods:
- Real-time quantitative PCR and bioinformatics analyses were used to assess LINC00324 expression in AML patient leukocytes and cell lines.
- Pearson correlation analysis examined the association of LINC00324 levels with various immunophenotypic markers and blood cell counts.
- Publicly available datasets (cBioPortal) were analyzed to correlate LINC00324 expression with clinical characteristics in a larger AML cohort.
Main Results:
- LINC00324 expression was significantly down-regulated in the peripheral blood leukocytes of AML patients.
- LINC00324 levels showed significant correlations with specific immunophenotypes (e.g., CD33, CD117, CD11b, CD14, CD64) and red blood cell and platelet counts.
- Down-regulation of LINC00324 was also observed in myeloid leukemia cell lines, and its expression negatively correlated with peripheral blood blast percentage and white blood cell count in tumor samples.
Conclusions:
- LINC00324 plays a role in the immune cell landscape of AML, potentially influencing immune cell differentiation, development, and function.
- The down-regulation and correlations observed suggest LINC00324 as a potential novel therapeutic target or biomarker for AML.
- Further research into LINC00324's precise mechanisms in AML pathogenesis may pave the way for new treatment strategies.
Abstract:
Objective To investigate the relationship between long-chain intergenic non-coding RNA324 (LINC00324) and immunophenotype in peripheral blood leukocytes of acute myeloid leukemia (AML) patients. Methods Real-time quantitative PCR and bioinformatics databases were utilized to analyze the expression level of LINC00324 in peripheral blood leukocytes and cell lines KG-1, THP-1 and U937 in AML patients. The relationships of the expression level of LINC00324 with the red blood cell and platelet count, the expression levels of LINC00324 and immunophenotypes in 40 AML patients were analyzed by Person correlation analysis. The immunophenotypes included CD14, CD68, CD64, CD11b, CD4, CD45, CD33, HLA-DR, CD163, CD2, CD58, CD117, CD43, CD34, CD99, CD8, CD38, CD10, CD13, CD56, CD7, TdT, CD235a, CD138, CD61, MPO and CD19. Simultaneously, the cBioPortal database datasets (TCGA, NEJM 2013) were used to analyze the clinical characteristics of 173 AML patients, and to analyze the correlations between the expression level of LINC00324 and the peripheral blood blast percentage and white blood cell count in tumor samples. Results The expression of LINC00324 in peripheral blood leukocytes of AML patients was down-regulated, and its expression level was significantly correlated with immunophenotype CD33, red blood cell and platelet count. Analysis of bioinformatics database showed that LINC00324 was under-expressed in myeloid leukemia cell lines. The expression of LINC00324 in AML patients was associated with multiple immunophenotypes such as CD33, CD117, CD11b, CD14 and CD64 and was negatively correlated with peripheral blood blast percentage and white blood cell count. Conclusion LINC00324 may be involved in regulating the differentiation, development and function of immune cells, which providing a new strategy for the development of targeted drugs or treatment of AML.
More Related Videos
14:04Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018